Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
Part of paid clinical trials in Coronado, California.
- Sponsor
- CytoDyn, Inc.
- Study ID
- NCT04521114
- Phase
- PHASE2
- Status
- Completed
Conditions
- Nonalcoholic Steatohepatitis (NASH)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Placebo — DRUGPlacebo will be administered subcutaneously every week for 13 weeks.
- leronlimab 700 mg — DRUG700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
- leronlimab 350 mg — DRUG350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
Study Details
This is a phase II study of of Leronlimab (PRO 140)-Humanized monoclonal antibody to CCR5 in patients with Nonalcoholic Steatohepatitis (NASH).
Key Dates
- Start date
- Dec 1, 2020
- Status verified
- Jan 2023
- Primary completion
- Dec 29, 2021
- Completion
- Dec 29, 2021
Study Design
- Enrollment
- 87 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Leronlimab 700 mgLeronlimab 700 mg SC weekly injection
- Experimental: Leronlimab 350 mgLeronlimab 350 mg SC weekly injection
- Placebo Comparator: PlaceboPlacebo SC weekly injection
Primary Outcome Measure
MRI-PDFF Change From Baseline to Week 14 [ Time Frame: Change from baseline (day one, first day of treatment) to EOT (day 92, 13 weeks of treatment) ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Southern California Research Center | Coronado | California | 92118 | - |
| Meridien Research | Maitland | Florida | 32751 | - |
| Floridian Clinical Research | Miami Lakes | Florida | 33016 | - |
| Sensible Healthcare, LLC | Ocoee | Florida | 34761 | - |
| Center for Advanced Research & Education | Gainesville | Georgia | 30501 | - |
| Care United Research LLC | Forney | Texas | 75126 | - |
| American Research Corporation | San Antonio | Texas | 78215 | - |
Find similar trials in Coronado, CA
Related Studies
- Evaluating the Pharmacokinetics and Safety of MiricorilantPHASE1 · Recruiting · Corcept Therapeutics · San Antonio, Texas
- Evaluation of Miricorilant on Liver Fat in Patients With MASLDPHASE1 · Recruiting · Corcept Therapeutics · Columbia, Missouri